An open-label phase II trial of G-FLIP (low doses of gemcitabine, 5-FU, leucovorin, irinotecan & oxaliplatin), followed by G-FLIP-DM (G-FLIP + low doses of docetaxel & mitomycin C), used concurrently with ascorbic acid (AA), in patients with advanced pancreatic cancer.
2016 ◽
Vol 34
(15_suppl)
◽
pp. e15745-e15745
Keyword(s):
Phase Ii
◽
2020 ◽
Vol 5
(3)
◽
pp. 285-294
◽